Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

A Clinical Trial of Patients With Solid Tumours Receiving Granulocyte Colony Stimulating Factor as Primary Prophylaxis for Chemotherapy-induced Neutropenia, in a Docetaxel Based Regimen

Phase 4

Completed

Conditions: Neoplasms (no Otherwise Specified)

Interventions: Drug: LENOGRASTIM (GRANOGYTE 34)

First Posted Date: 2010-04-21

Last Posted Date: 2012-10-05

Lead Sponsor: Sanofi

Target Recruit Count: 403

Registration Number: NCT01107756

Locations: 🇿🇦
Investigational Site Number 27, Cape Town, South Africa
🇿🇦
Investigational Site Number 48, Rustenburg, South Africa
🇿🇦
Investigational Site Number 25, Somerset West, South Africa

and more 22 locations

Antibody Persistence in Healthy Children After Primary and Booster DTaP-IPV-Hep B-PRP-T Vaccine or Control Vaccine

Completed

Conditions: Diphtheria
Tetanus
Whooping Cough
Hepatitis B
Poliomyelitis

First Posted Date: 2010-04-16

Last Posted Date: 2011-12-13

Lead Sponsor: Sanofi

Target Recruit Count: 455

Registration Number: NCT01105559

Elitek (Rasburicase) Immuno-Monitoring Study

Terminated

Conditions: Tumor Lysis Syndrome

First Posted Date: 2010-04-01

Last Posted Date: 2013-01-31

Lead Sponsor: Sanofi

Target Recruit Count: 1

Registration Number: NCT01097369

Locations: 🇺🇸
Investigational Site Number 2, Memphis, Tennessee, United States
🇺🇸
Investigational Site Number 4, Oklahoma City, Oklahoma, United States
🇺🇸
Investigational Site Number 1, Houston, Texas, United States

and more 1 locations

Sleep Satisfaction and Psychomotor Performance of Adults

Phase 4

Completed

Conditions: Sleep Disorders

Interventions: Drug: ZOLPIDEM

First Posted Date: 2010-04-01

Last Posted Date: 2012-07-17

Lead Sponsor: Sanofi

Target Recruit Count: 30

Registration Number: NCT01097382

Locations: 🇦🇷
Investigational Site Number 4, C.a.b.a., Argentina
🇦🇷
Investigational Site Number 10, Buenos Aires, Argentina
🇦🇷
Investigational Site Number 1, C.a.b.a., Argentina

and more 3 locations

Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel and Cisplatin in Patients With Solid Tumors

Phase 1

Completed

Conditions: Neoplasms, Malignant

Interventions: Drug: OMBRABULIN (AVE8062)
Drug: cisplatin
Drug: docetaxel

First Posted Date: 2010-03-30

Last Posted Date: 2013-10-16

Lead Sponsor: Sanofi

Target Recruit Count: 11

Registration Number: NCT01095302

Locations: 🇯🇵
Investigational Site Number 392001, Koto-Ku, Japan
🇯🇵
Investigational Site Number 392003, Akashi-Shi, Japan
🇯🇵
Investigational Site Number 392002, Nagoya-Shi, Japan

Oral Glutamine in the Prevention of Oxaliplatin-induced Neurotoxicity

Phase 3

Completed

Conditions: Colorectal Neoplasms

Interventions: Drug: Calcium and Magnesium
Drug: Glutamine

First Posted Date: 2010-03-16

Last Posted Date: 2013-06-21

Lead Sponsor: Sanofi

Target Recruit Count: 200

Registration Number: NCT01087658

Locations: 🇨🇦
Investigational Site Number 0001, Greenfield Park, Canada
🇨🇦
Investigational Site Number 124-011, Montreal, Canada
🇨🇦
Investigational Site Number 124-003, Quebec, Canada

and more 11 locations

Effect of Cabazitaxel on the QTc Interval in Cancer Patients

Phase 1

Completed

Conditions: Neoplasms, Malignant

Interventions: Drug: Cabazitaxel (XRP6258)

First Posted Date: 2010-03-15

Last Posted Date: 2011-12-16

Lead Sponsor: Sanofi

Target Recruit Count: 45

Registration Number: NCT01087021

Locations: 🇧🇪
Sanofi-Aventis Investigational Site Number 056002, Bruxelles, Belgium
🇺🇸
Sanofi-Aventis Investigational Site Number 840006, San Diego, California, United States
🇺🇸
Sanofi-Aventis Investigational Site Number 840005, Decatur, Illinois, United States

and more 12 locations

SAR240550 in Combination With Gemcitabine/Cisplatin in Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer Stage IV

Interventions: Drug: Iniparib
Drug: gemcitabine
Drug: cisplatin

First Posted Date: 2010-03-15

Last Posted Date: 2013-09-24

Lead Sponsor: Sanofi

Target Recruit Count: 119

Registration Number: NCT01086254

Locations: 🇫🇷
Sanofi-Aventis Investigational Site Number 250003, Marseille Cedex 09, France
🇫🇷
Sanofi-Aventis Investigational Site Number 250002, Caen Cedex, France
🇩🇪
Sanofi-Aventis Investigational Site Number 276003, Essen, Germany

and more 11 locations

A Study of Meningococcal Vaccine, Menactra® in Healthy Subjects in India

Phase 3

Completed

Conditions: Meningococcal Infection
Meningitis

Interventions: Biological: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate (Menactra®)

First Posted Date: 2010-03-15

Last Posted Date: 2012-02-06

Lead Sponsor: Sanofi

Target Recruit Count: 300

Registration Number: NCT01086969

Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies

Phase 1

Completed

Conditions: Hematological Malignancy

Interventions: Drug: Isatuximab SAR650984
Drug: Dexamethasone

First Posted Date: 2010-03-10

Last Posted Date: 2024-11-01

Lead Sponsor: Sanofi

Target Recruit Count: 351

Registration Number: NCT01084252

Locations: 🇪🇸
Investigational Site Number : 724008, Sevilla, Spain
🇹🇷
Investigational Site Number : 792002, Ankara, Turkey
🇹🇷
Investigational Site Number : 792005, Ankara, Turkey

and more 56 locations

Home Terms & Conditions Privacy Policy